Pacira BioSciences Executive Kristen Williams Has Sold $14M in PCRX Stock — Annual Pattern Continues

Kristen Williams, an executive at Pacira BioSciences (PCRX), has sold $14 million in company stock across 141 transactions in a remarkably consistent annual pattern.

The Numbers

Metric	Value
Career Sell Value	$14.0M
Career Buy Value	$0
Total Transactions	141
Last Transaction	2026-02-02
Shares Remaining	131,303

Recent Activity

Date	Type	Shares	Price	Est. Value
2026-02-02	Sell	13,137	$20.5300	$270K
2025-06-04	Sell	14,376	$26.2400	$377K
2024-06-13	Sell	7,452	$28.3800	$211K
2023-06-14	Sell	6,467	$37.0300	$239K
2023-06-07	Sell	1,357	$37.8650	$51K

Williams sold 13,137 shares at $20.53 on February 2, 2026, for approximately $270K. Her pattern shows annual selling clusters — June 2025 ($377K), June 2024 ($211K), June 2023 ($290K), June 2022 ($521K) — suggesting a recurring 10b5-1 plan execution window.

What It Means

Williams' selling follows a textbook 10b5-1 pattern: clustered disposals once or twice per year, typically around the same calendar months. The declining per-trade values — from $521K in 2022 to $270K in 2026 — mirror PCRX's share price erosion from $60+ to $20, not changes in her selling behavior.

For PCRX investors, Williams' 131,303 remaining shares represent meaningful continued exposure. Pacira's non-opioid pain management portfolio faces both opportunity and competition as the healthcare industry navigates post-opioid-crisis treatment paradigms. The consistent selling without acceleration at declining prices is modestly constructive.

What to Watch

• PCRX share price trajectory and pain management market share
• Whether Williams adjusts her selling plan at $20 price levels
• FDA updates on Pacira's Exparel and iovera portfolios
• Other PCRX insider activity for corroborating signals